biogen inc said european patent office granted patent covering certain proteins used produce hepatitis vaccine through genetic engineering techniques robert gottlieb biogen spokesman said company has licensed vaccine nonexclusive basis british pharmaceutical firm and discussing licensing with companies biogen said patent gives right exclude others from marketing hepatitis vaccine member countries european patent convention gottlieb said company has also filed patent markets including vaccine clinical tests patents biotechnology field particularly important company with exclusive patent can reap large rewards recently many products genetic engineering have target patent lawsuits merck and inc already sells genetically engineered hepatitis vaccine called recombivax subsidiary smithkline biologicals based belgium selling hepatitis vaccine called engerix belgium smithkline spokesman said vaccine has also been formally approved switzerland and luxembourg and has been authorized for market number far east countries hepatitis serious liver infection common many parts africa and southeast asia about five pct pct population carry virus about 200 000 new cases occur each year last december european patent ofice rejected biogen patent for alpha interferon which biogen said will appeal once receives formal written opinion from office reuter 